Skip to main content
SpringerLink
Log in

Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy

  • Review Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

The burden of cardiovascular disease (CVD) is continuously and progressively raising worldwide. Essential hypertension is a major driver of cardiovascular events, including coronary artery disease, myocardial infarction, ischemic stroke and congestive heart failure. This latter may represent the final common pathway of different cardiovascular diseases, and it is often mediated by progressive uncontrolled hypertension. Despite solid advantages derived from effective and sustained blood pressure control, and the widespread availability of effective antihypertensive medications, the vast majority of the more than 1 billion hypertensive patients worldwide continue to have uncontrolled hypertension. Among various factors that may be involved, the abnormal activation of neurohormonal systems is one consistent feature throughout the continuum of cardiovascular diseases. These systems may initiate biologically meaningful “injury responses”. However, their sustained chronic overactivity often may induce and maintain the progression from hypertension towards congestive heart failure. The renin–angiotensin–aldosteron system, the sympathetic nervous system and the endothelin system are major neurohormonal stressor systems that are not only able to elevate blood pressure levels by retaining water and sodium, but also to play a role in the pathophysiology of cardiovascular diseases. More recently, the angiotensin receptor neprilysin inhibitor (ARNI) represents a favourable approach to inhibit neutral endopeptidase (NEP) and suppress the RAAS via blockade of the AT1 receptors, without the increased risk of angioedema. LCZ696, the first-in-class ARNI, has already demonstrated BP lowering efficacy in patients with hypertension, in particular with respect to systolic blood pressure levels, improved cardiac biomarkers, cardiac remodelling and prognosis in patients with heart failure. This manuscript will briefly overview the main pathophysiological and therapeutic aspects of ARNI in the clinical management of hypertension and heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

    Article  PubMed  Google Scholar 

  2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.

    Article  CAS  PubMed  Google Scholar 

  4. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50.

    Article  PubMed  Google Scholar 

  5. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33:1058–66.

    Article  CAS  PubMed  Google Scholar 

  6. Volpe M, Cosentino F, Tocci G, et al. Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep. 2011;13:318–24.

    Article  CAS  PubMed  Google Scholar 

  7. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367–74.

    Article  CAS  PubMed  Google Scholar 

  8. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605.

    Article  Google Scholar 

  9. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247:F863–6.

    CAS  PubMed  Google Scholar 

  10. Wada A, Tsutamoto T, Matsuda Y, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 1994;89:2232–40.

    Article  CAS  PubMed  Google Scholar 

  11. Stevens SM Jr, Kem WR, Prokai L. Investigation of cytolysin variants by peptide mapping: enhanced protein characterization using complementary ionization and mass spectrometric techniques. Rapid Commun Mass Spectrom. 2002;16:2094–101.

    Article  CAS  PubMed  Google Scholar 

  12. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680–5.

    Article  CAS  PubMed  Google Scholar 

  13. Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–40.

    Google Scholar 

  14. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.

    Article  CAS  PubMed  Google Scholar 

  15. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs. 2001;10:935–42.

    Article  CAS  PubMed  Google Scholar 

  16. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643–52.

    Article  CAS  PubMed  Google Scholar 

  17. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.

    Article  CAS  PubMed  Google Scholar 

  18. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–5.

    Article  CAS  PubMed  Google Scholar 

  19. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.

    Article  CAS  PubMed  Google Scholar 

  20. Kerr MA, Kenny AJ. The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem J. 1974;137:489–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Malfroy B, Swerts JP, Guyon A, et al. High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature. 1978;276:523–6.

    Article  CAS  PubMed  Google Scholar 

  22. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11:355–64.

    CAS  PubMed  Google Scholar 

  23. Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243:183–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241:237–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Vijayaraghavan J, Scicli AG, Carretero OA, et al. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265:14150–5.

    CAS  PubMed  Google Scholar 

  26. Shima M, Seino Y, Torikai S, et al. Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments. Life Sci. 1988;43:357–63.

    Article  CAS  PubMed  Google Scholar 

  27. Graf K, Koehne P, Grafe M, et al. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 1995;26:230–5.

    Article  CAS  PubMed  Google Scholar 

  28. Dussaule JC, Stefanski A, Bea ML, et al. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol. 1993;264:F45–52.

    CAS  PubMed  Google Scholar 

  29. Standeven KF, Hess K, Carter AM, et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35:1031–40.

    Article  CAS  Google Scholar 

  30. Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323–30.

    Article  CAS  PubMed  Google Scholar 

  31. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17:S37–43.

    CAS  PubMed  Google Scholar 

  32. Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002;105:639–44.

    Article  CAS  PubMed  Google Scholar 

  33. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy. 2010;40:50–61.

    CAS  PubMed  Google Scholar 

  34. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002;359:2088–9.

    Article  CAS  PubMed  Google Scholar 

  35. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.

    Article  CAS  PubMed  Google Scholar 

  36. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

    Article  CAS  PubMed  Google Scholar 

  37. Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens. 2015 [Epub ahead of print].

  38. Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.

    Article  CAS  PubMed  Google Scholar 

  39. Williams B, Cockcroft JR, Kario K, et al. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open. 2014;4:e004254.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528–38.

    Article  CAS  PubMed  Google Scholar 

  41. Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886–93c.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.

    Article  CAS  PubMed  Google Scholar 

  43. Tatoulis J. Coronary revascularization in heart failure-old lessons relearnt: patient outcomes are paramount in the stenting era. Eur J Cardiothorac Surg. 2015;47:322–3.

    Article  PubMed  Google Scholar 

  44. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    Article  PubMed  Google Scholar 

  45. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.

    Article  CAS  PubMed  Google Scholar 

  46. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.

    Article  CAS  PubMed  Google Scholar 

  47. Fox KM. Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.

    Article  CAS  PubMed  Google Scholar 

  48. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Squire IB, O’Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond). 2004;107:309–16.

    Article  CAS  Google Scholar 

  50. Makikallio AM, Makikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke. 2005;36:1016–20.

    Article  CAS  PubMed  Google Scholar 

  51. Kasama S, Furuya M, Toyama T, et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008;29:1485–94.

    Article  CAS  PubMed  Google Scholar 

  52. Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2007;49:667–74.

    Article  CAS  PubMed  Google Scholar 

  53. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.

    Article  CAS  PubMed  Google Scholar 

  54. Chen HH, Martin FL, Gibbons RJ, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009;95:1315–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Via di Grottarossa 1035-1039, 00189, Rome, Italy

    M. Volpe, G. Tocci, A. Battistoni & S. Rubattu

  2. IRCCS Neuromed, Pozzilli, IS, Italy

    M. Volpe, G. Tocci & S. Rubattu

Authors
  1. M. Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Tocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Battistoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Rubattu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Volpe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volpe, M., Tocci, G., Battistoni, A. et al. Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. High Blood Press Cardiovasc Prev 22, 241–246 (2015). https://doi.org/10.1007/s40292-015-0112-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-015-0112-5

Keywords

Search

Navigation